The market capitalization or net worth of Emergent BioSolutions (NYSE: EBS) sits at approximately $238 million, reflecting recent valuation adjustments, historical share price pullbacks, and broader small-cap biotech sector dynamics. While its overall enterprise value fluctuates daily based on trading volume and quarterly revenue reports from its medical countermeasure contracts, its net asset base provides institutional backing alongside its public equity valuation.